GlycoEra has developed a game-changing protein engineering and production platform to build a high-value pipeline of medicines based on deep expertise in glycobiology. Our innovative, first-in-class product candidates will treat diseases with high unmet medical need in autoimmune, oncology, neurology and infectious disease indications. GlycoEra is advancing a range of assets towards human clinical studies.
GlycoEra’s CustomGlycan platform enables recombinant biologics with precise, and controlled glycosylation in a site-specific manner. Using our proprietary CustomGlycan platform, GlycoEra is developing novel, fully human, biological products that exploit natural glycan mediated pathways. With its platform technology and robust discovery engine, GlycoEra has generated novel assets to treat very challenging diseases.